Linifanib

Generic Name
Linifanib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C21H18FN5O
CAS Number
796967-16-3
Unique Ingredient Identifier
CO93X137CW
Background

Linifanib (ABT-869) is a small molecule vascular endothelial growth factor (VEGF) receptor-based kinase inhibitor that is designed to suppress tumor growth by preventing the formation of new blood vessels that supply the tumor with oxygen and nutrients and by inhibiting key angiogenic signaling pathways. Linifanib is intended for the treatment of hematologic...

Indication

Investigated for use/treatment in leukemia (myeloid), myelodysplastic syndrome, and solid tumors.

Associated Conditions
-
Associated Therapies
-

A Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors

Phase 1
Terminated
Conditions
Interventions
First Posted Date
2012-01-10
Last Posted Date
2012-08-28
Lead Sponsor
Abbott
Target Recruit Count
14
Registration Number
NCT01506934
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Site Reference ID/Investigator# 61282, Detroit, Michigan, United States

๐Ÿ‡บ๐Ÿ‡ธ

Site Reference ID/Investigator# 52122, San Antonio, Texas, United States

๐Ÿ‡บ๐Ÿ‡ธ

Site Reference ID/Investigator# 51463, Lebanon, New Hampshire, United States

and more 1 locations

An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastatic Solid Tumors

Phase 1
Completed
Conditions
Interventions
First Posted Date
2011-08-10
Last Posted Date
2017-11-21
Lead Sponsor
AbbVie
Target Recruit Count
35
Registration Number
NCT01413893

Effect of Rifampin on the Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors

Phase 1
Completed
Conditions
Interventions
First Posted Date
2011-07-26
Last Posted Date
2011-11-02
Lead Sponsor
Abbott
Target Recruit Count
14
Registration Number
NCT01401933
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Site Reference ID/Investigator# 49952, Madison, Wisconsin, United States

๐Ÿ‡บ๐Ÿ‡ธ

Site Reference ID/Investigator# 49953, Tucson, Arizona, United States

To Compare Relative Bioavailability of Two Clinical Formulations of Linifanib.

Phase 1
Completed
Conditions
Interventions
First Posted Date
2011-06-27
Last Posted Date
2012-03-23
Lead Sponsor
Abbott
Target Recruit Count
13
Registration Number
NCT01381341
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Site Reference ID/Investigator# 51403, Tacoma, Washington, United States

Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer

First Posted Date
2011-06-03
Last Posted Date
2014-08-26
Lead Sponsor
Vanderbilt-Ingram Cancer Center
Target Recruit Count
30
Registration Number
NCT01365910
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Vanderbilt Cool Springs, Franklin, Tennessee, United States

๐Ÿ‡บ๐Ÿ‡ธ

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC)

First Posted Date
2010-10-21
Last Posted Date
2017-11-21
Lead Sponsor
AbbVie
Target Recruit Count
12
Registration Number
NCT01225302
ยฉ Copyright 2024. All Rights Reserved by MedPath